Germany · Delayed Price · Currency is EUR Biotechnology Assets Statistics
Total Valuation
BST:041 has a market cap or net worth of EUR 24.49 million. The enterprise value is 26.31 million.
| Market Cap | 24.49M |
| Enterprise Value | 26.31M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 68.03M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.28% |
| Shares Change (QoQ) | +7.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.26 |
| PB Ratio | 3.71 |
| P/TBV Ratio | 5.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.02 |
| EV / Sales | 8.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -300.30 |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of 0.32.
| Current Ratio | 0.81 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -23.81 |
| Interest Coverage | -12.62 |
Financial Efficiency
Return on equity (ROE) is -44.40% and return on invested capital (ROIC) is -14.77%.
| Return on Equity (ROE) | -44.40% |
| Return on Assets (ROA) | -9.11% |
| Return on Invested Capital (ROIC) | -14.77% |
| Return on Capital Employed (ROCE) | -22.36% |
| Revenue Per Employee | 87,210 |
| Profits Per Employee | -85,803 |
| Employee Count | 34 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -139,119 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +97.78% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +97.78% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.24 |
| Relative Strength Index (RSI) | 46.82 |
| Average Volume (20 Days) | 10,515 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BST:041 had revenue of EUR 2.97 million and -2.92 million in losses. Loss per share was -0.04.
| Revenue | 2.97M |
| Gross Profit | 2.62M |
| Operating Income | -2.29M |
| Pretax Income | -3.06M |
| Net Income | -2.92M |
| EBITDA | -1.29M |
| EBIT | -2.29M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 261,856 in cash and 2.09 million in debt, giving a net cash position of -1.82 million.
| Cash & Cash Equivalents | 261,856 |
| Total Debt | 2.09M |
| Net Cash | -1.82M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.61M |
| Book Value Per Share | 0.10 |
| Working Capital | -851,300 |
Cash Flow
In the last 12 months, operating cash flow was -73,854 and capital expenditures -13,765, giving a free cash flow of -87,619.
| Operating Cash Flow | -73,854 |
| Capital Expenditures | -13,765 |
| Free Cash Flow | -87,619 |
| FCF Per Share | n/a |
Margins
Gross margin is 88.19%, with operating and profit margins of -77.17% and -98.39%.
| Gross Margin | 88.19% |
| Operating Margin | -77.17% |
| Pretax Margin | -103.08% |
| Profit Margin | -98.39% |
| EBITDA Margin | -43.60% |
| EBIT Margin | -77.17% |
| FCF Margin | n/a |
Dividends & Yields
BST:041 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.28% |
| Shareholder Yield | n/a |
| Earnings Yield | -11.91% |
| FCF Yield | -0.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BST:041 has an Altman Z-Score of -8.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.07 |
| Piotroski F-Score | 2 |